Cite
HARVARD Citation
Ali, S. et al. (2020). European Medicines Agency extension of indication to include the combination immunotherapy cancer drug treatment with nivolumab (Opdivo) and ipilimumab (Yervoy) for adults with intermediate/poor-risk advanced renal cell carcinoma. ESMO open. 5 (6), p. . [Online].